Contractile forces in platelet aggregates under microfluidic shear gradients reflect platelet inhibition and bleeding risk

Nat Commun. 2019 Mar 13;10(1):1204. doi: 10.1038/s41467-019-09150-9.

Abstract

Platelets contract forcefully after their activation, contributing to the strength and stability of platelet aggregates and fibrin clots during blood coagulation. Viscoelastic approaches can be used to assess platelet-induced clot strengthening, but they require thrombin and fibrin generation and are unable to measure platelet forces directly. Here, we report a rapid, microfluidic approach for measuring the contractile force of platelet aggregates for the detection of platelet dysfunction. We find that platelet forces are significantly reduced when blood samples are treated with inhibitors of myosin, GPIb-IX-V, integrin αIIbβ3, P2Y12, or thromboxane generation. Clinically, we find that platelet forces are measurably lower in cardiology patients taking aspirin. We also find that measuring platelet forces can identify Emergency Department trauma patients who subsequently require blood transfusions. Together, these findings indicate that microfluidic quantification of platelet forces may be a rapid and useful approach for monitoring both antiplatelet therapy and traumatic bleeding risk.

Publication types

  • Observational Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Video-Audio Media

MeSH terms

  • Adult
  • Aspirin / pharmacology
  • Aspirin / therapeutic use
  • Blood Coagulation / drug effects
  • Blood Platelets / drug effects
  • Blood Platelets / physiology*
  • Computer Simulation
  • Cross-Sectional Studies
  • Drug Monitoring / methods
  • Female
  • Hemorrhage / diagnosis*
  • Hemorrhage / etiology
  • Hemorrhage / therapy
  • Humans
  • Male
  • Microfluidics / methods*
  • Middle Aged
  • Myosins / antagonists & inhibitors
  • Myosins / metabolism
  • Platelet Aggregation / drug effects
  • Platelet Aggregation / physiology*
  • Platelet Aggregation Inhibitors / pharmacology*
  • Platelet Aggregation Inhibitors / therapeutic use
  • Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors
  • Platelet Glycoprotein GPIIb-IIIa Complex / metabolism
  • Platelet Glycoprotein GPIb-IX Complex / antagonists & inhibitors
  • Platelet Glycoprotein GPIb-IX Complex / metabolism
  • Prognosis
  • Thromboxane A2 / metabolism
  • Wounds and Injuries / blood
  • Wounds and Injuries / complications*
  • Wounds and Injuries / therapy

Substances

  • Platelet Aggregation Inhibitors
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Platelet Glycoprotein GPIb-IX Complex
  • Thromboxane A2
  • Myosins
  • Aspirin